Joshua K. Sabari
NYU Langone Health · 313 works · 10,338 citations · h-index 43
Top works
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
- Unravelling the biology of SCLC: implications for therapy
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)
- Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
- Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
- Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
- Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
- Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
- Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
- A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers
- JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
- Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
- Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
- Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers